НОВЫЕ ВОЗМОЖНОСТИ КОМБИНИРОВАННОЙ ТЕРАПИИ АЛЛЕРГИЧЕСКОГО РИНИТА В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ

2019 ◽  
Author(s):  
E.V. Nazarova
Keyword(s):  
Allergic Conjunctivitis ◽  
Nasal Congestion ◽  
Nasal Breathing ◽  
Interferon Alpha 2B ◽  
Complex Therapy ◽  
Eye Symptoms ◽  
Low Incidence ◽  
The Given ◽  
Combined Medication ◽  
Real Clinical Practice

Статья представляет собой обзор исследовательской программы по оценке эффективности оригинального комбинированного лекарственного препарата Аллергоферон бета (бетаметазон интерферон альфа-2b) в условиях реальной клинической практики у больных сезонным аллергическим ринитом (АР). Результаты программы продемонстрировали хорошую эффективность препарата: при низкой частоте побочных эффектов наблюдалось снижение заложенности носа и восстановление носового дыхания, у пациентов с сопутствующим аллергическим конъюнктивитом отмечалось снижение выраженности глазных симптомов. Было показано, что Аллергоферон бета может быть рекомендован в качестве монотерапии у больных АР с легким и среднетяжелым течением заболевания и в комплексной терапии при тяжелом течении АР.This paper assesses the efficacy of the original combined medication Allergoferon beta (betamethasone interferon alpha-2b) in real clinical practice among patients with seasonal allergic rhinitis (AR). The research program results demonstrated a good efficacy of the given medication: there were a decrease in nasal congestion as well as restoration of nasal breathing and in patients with concomitant allergic conjunctivitis - a reduction in the severity of eye symptoms. A low incidence of side effects was observed. It was shown that Allergoferon beta can be recommended as monotherapy for patients with mild and moderate AR and in complex therapy for patients with severe AR.

scholarly journals New opportunities for the combined therapy of allergic rhinitis in real clinical practice

2019 ◽  
Vol 16 (1) ◽  
pp. 85-89
Author(s):  
E V Nazarova
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Practice ◽  
Nasal Congestion ◽  
Combined Therapy ◽  
Nasal Breathing ◽  
Interferon Alpha 2B ◽  
Eye Symptoms ◽  
Low Incidence ◽  
The Given ◽  
Real Clinical Practice

This paper assesses the efficacy of the original combined medication Allergoferon® beta (betamethasone + interferon alpha-2b) in real clinical practice among patients with seasonal allergic rhinitis (AR). The research program results demonstrated a good efficacy of the given medication: there were a decrease in nasal congestion as well as restoration of nasal breathing and in patients with concomitant allergic conjunctivitis - a reduction in the severity of eye symptoms. A low incidence of side effects was observed. It was shown that Allergoferon® beta can be recommended as monotherapy for patients with mild and moderate AR and in complex therapy for patients with severe AR.

scholarly journals The effects of nasal breathing on the development of snoring and apnea

2020 ◽  
pp. 89-94
Author(s):  
Svetlana E. Yaremchuk
Keyword(s):  
Sleep Quality ◽  
Nasal Congestion ◽  
Upper Airway ◽  
Case Control Studies ◽  
Nasal Breathing ◽  
Adequate Treatment ◽  
Randomized Controlled ◽  
Breathing Disorders ◽  
Nasal Steroids ◽  
Improve Sleep Quality

Since the nose is the entrance gate of the upper airway, its stuffiness can contribute to sleep disturbance. The results of a number of case-control studies have shown that nasal congestion frequency associated with snoring and mild OSA. However, there is no strong correlation between the degree of nasal obstruction and the severity of OSA. Randomized controlled trials have shown that in patients with rhinitis, both allergic and non-allergic, the use of nasal steroids can improve sleep quality and may be useful for patients with mild OSA, but they themselves are not an adequate treatment. Surgical correction of nasal breathing disorders also reduces the apnea index and improves sleep quality.

Perceptual and physiologic effects of nasal congestion on nasal breathing

1997 ◽  
Vol 117 (2) ◽  
pp. P139-P139
Author(s):  
A LANE ◽  
D WARREN ◽  
A DRAKE
Keyword(s):  
Nasal Congestion ◽  
Nasal Breathing

scholarly journals Correlation of Features of Allergic Rhinitis and Allergic Conjunctivitis with Treatment Modalities

2019 ◽  
pp. 1-10 ◽  
Author(s):  
Shuaib Kayode Aremu ◽  
Tayo Ibrahim ◽  
Azeez Oyemomi Ibrahim ◽  
Popoola Tomilayo Ajoke
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Conjunctivitis ◽  
Nasal Congestion ◽  
Nasal Symptom ◽  
Treatment Modalities ◽  
Nasal Discharge ◽  
Southwestern Nigeria ◽  
Cross Sectional ◽  
Female Ratio ◽  
Eye Pain

Introduction: Allergic Rhinitis (AR) is a chronic, symptomatic allergic disorder of the nose that is usually caused by IgE-mediated inflammatory response following exposure to an allergen. The allergen could be in the form of dust, pollen, flower, animal dander, mold, cold, food allergens or insect. Clinically, AR occurs when there are recurrent nasal symptoms which are reversible either spontaneously or with medication in the preceding one year. Such symptoms include at least two of the following; excessive sneezing, running nose, nasal itching, nasal discharge, nasal congestion or obstruction. Previous studies have linked AR to be co-existed with another form of allergic disorders including AC, Atopic dermatitis and Allergic Asthma. This study is aimed at assessing the feature of  AR patients with coexistent AC as well as evaluating the effectiveness of the treatments offered to them. Objectives: The study was aimed at finding the correlation between the nasal and eye features in a patient who has co-existing allergic rhinitis and allergic conjunctivitis. Methodology: This was a cross-sectional descriptive study conducted between August 2018 and November 2019 among 38 patients who presented to ENT and Ophthalmology departments of Federal Teaching Hospital Ido-Ekiti, Ekiti State, Southwestern Nigeria and was diagnosed with both allergic rhinitis and allergic conjunctivitis. Relevant data obtained were analyzed using SPSS version 20.  P ≤ 0.05 was taken as significant. Results: The patients’ age range between 8 and 81 years with a median age of 33 years. The majority were less than 45 years (63.2%) with the male to female ratio of almost. Eye pain, itching, and redness account for 97.4% of all the eye features, while the presence of Cobblestone-like papillae is the least and accounted for 5%. Nasal itching (92.1%) was the commonest nasal symptom. Sleep disturbance was found to be the most common among those with eye itching (29.7%). Conclusion: This research was conducted to correlate the features of allergic rhinitis with those of conjunctivitis and common management and preventive measures offered to the patients seen in our clinics. The majority of the patients were less than 45 years with almost equal sex ratio. Eye pain, itching, and redness account for the majority of all the eye features, while the presence of Cobblestone-like papillae is the least eye feature. Nasal itching was the commonest nasal symptom and this was seen in the majority of the patients with eye symptoms.

scholarly journals Nasal decongestants in the treatment of nasal obstruction

2021 ◽  
pp. 120-124
Author(s):  
K. A. Nikitin ◽  
S. V. Baranskaya
Keyword(s):  
Nasal Obstruction ◽  
Nasal Mucosa ◽  
Ph Value ◽  
Nasal Congestion ◽  
Pathological Process ◽  
Buffer System ◽  
Nasal Breathing ◽  
Structural Problems ◽  
Nasal Decongestants ◽  
Nasal Valve Collapse

Nasal congestion is one of the most common symptoms of common colds and rhinitis, due to an inflammatory reaction, vasodilation, increased nasal blood flow and vascular permeability. Nasal obstruction is often a multifactorial problem, in addition to infectious causes, it can be caused by a combination of anatomical aberrations, swelling of the nasal mucosa and enlargement of the turbinates. Anatomical and structural problems, such as nasal septum deviation and nasal valve collapse, are usually treated surgically. Drug therapy of nasal obstruction is aimed at reducing edema and inflammation of the nasal mucosa. Pharmacotherapy of nasal obstruction is aimed at reducing inflammation and/or swelling of the mucous membrane. Decongestants are widely prescribed to relieve symptoms. The drugs used have different mechanisms of action and include systemic and topical drugs. This article discusses decongestants as a treatment for nasal obstruction. When applied topically, the drugs of this group act directly on the α2 and α1-adrenergic receptors of the nasal cavity, causing vasoconstriction, a decrease in the volume of the nasal conch, an increase in nasal patency, and relieving the symptoms of obstruction. The existing risk of developing side effects, both systemic and local, is reduced with atopic exposure and proper dosing of the drug used. Preferably, the use of drugs with low bioavailability. The suppression of the ciliated epithelium can be caused not only by the pathological process, but also by the composition of drugs. The value is given to the acidity of the buffer system. The optimal pH value of intranasal agents is about 6 (neutral range). The combination with anticholinesterase substances reduces the production of pathological discharge. The use of multi-component medicines allows you to restore nasal breathing and suppress excessive nasal secretion. One of the effective and safe drugs of topical action is Xylometazoline, as a monocomponent agent or in combination with ipratropium bromide.

scholarly journals The use of nasal decongestants to correction the respiratory and olfactory function of the nose

2019 ◽  
pp. 60-65 ◽  
Author(s):  
S. V. Morozova ◽  
L. A. Toporkova
Keyword(s):  
Nasal Cavity ◽  
Nasal Obstruction ◽  
Paranasal Sinuses ◽  
Nasal Congestion ◽  
Olfactory Function ◽  
Nasal Discharge ◽  
Nasal Breathing ◽  
Nasal Decongestants ◽  
Osteomeatal Complex ◽  
Tube Dysfunction

One of the main functions of the nose is respiratory and olfactory. Difficulty in nasal breathing, nasal congestion, nasal discharge can complicate the respiratory and olfactory functions of the nose or make them impossible. Most often the cause is swelling of the mucous. Nasal obstruction and rhinorrhea are the most common symptoms in diseases of the nasal cavity and paranasal sinuses. Of great importance is the use of local vasoconstrictors to eliminate swelling in the nasal cavity and prevent complications associated with auditory tube dysfunction. It is proved that the use of nasal decongestants helps to reduce swelling in the nasal cavity and in the osteomeatal complex. Otrivin Moisturizing formula, Otrivin Menthol, Otrivin Complex and Otrivin Sea are effective and well tolerated means to eliminate swelling in the nasal cavity and reduce nasal discharge and rehabilitation of olfactory function.

scholarly journals Efektivitas Pelargonium sidoides terhadap penurunan gejala rinosinusitis kronik alergi tanpa polip disertai gangguan tidur

2014 ◽  
Vol 44 (1) ◽  
pp. 26
Author(s):  
Ahmad Juwaeni ◽  
Teti Madiadipoera ◽  
Iwin Soemarman ◽  
Sinta Sari Ratunanda
Keyword(s):  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Sleep Disturbances ◽  
Nasal Congestion ◽  
Analog Scale ◽  
Pelargonium Sidoides ◽  
Tnf Α ◽  
Quasi Experimental ◽  
Eye Symptoms

Latar Belakang: Rinosinusitis kronik tanpa polip adalah inflamasi mukosa hidung dan sinus paranasal lebih dari 12 minggu. Etiologinya multifaktorial, terbanyak alergi. Gejala utamanya kongesti hidung, hidung berair, nyeri wajah, gangguan penciuman, dan menyebabkan gangguan tidur. Gangguan tidur disebabkan kongesti hidung dan peningkatan mediator inflamasi IL-1, IL-6, dan TNF-α. Tujuan: Membuktikan efektivitas terapi adjuvan rinosinusitis kronik alergi tanpa polip disertai gangguan tidur menggunakan ekstrak Pelargonium sidoides. Perbaikan gejala dan tanda klinis, serta penurunan kadar IL-1, IL-6, dan TNF- α sekret hidung sebagai indikator. Metode: Quasi-experimental open labelledpre and posttest design pada 20 sampel, dibagi menjadi dua kelompok. Kelompok pertama diterapi larutan cuci hidung NaCl isotonis, semprot hidung kortikosteroid dan ekstrak Pelargonium sidoides. Kelompok kedua (kontrol) tidak diberikan ekstrak Pelargonium sidoides. Gejala klinis dinilai dengan Total Nasal Score Symptoms (TNSS), Visual Analog Scale (VAS), dan nasoendoskopi. Kualitas hidup dengan Rhinoconjuntivitis Quality of Life Questionnaires (RQLQ), dan Sinonasal Outcame Test-20 (SNOT-20). Hasil: Penurunan skor Total Nasal Score Symptoms (TNSS) (p=0,001), Visual Analog Scale (VAS) hidung tersumbat (p=0.018), VAS hidung berair (p=0,02), VAS nyeri wajah (p=0,008),skor nasoendoskopi (p=0,03), dan Rhinoconjuntivitis Quality of Life Questionnaires (RQLQ) activity (p=0,003), sleep (p=0,001), non-nose/eye symptoms (p=0,005), dan emotional (p=0,01) pada kelompok perlakuan berbeda bermakna dibandingkan kelompok kontrol berdasarkan uji Mann-Whitney. Tidak ada perbedaan bermakna pada skor SNOT-20 (p=0,096), penurunan kadar IL-1 (p=0,529), IL-6 (p=0,529), dan TNF-α (p=0,971). Kesimpulan: ekstrak Pelargonium sidoides secara klinis efektif sebagai terapiadjuvan rinosinusitis kronik alergi tanpa polip disertai gangguan tidur, namun tidak didukung penurunan kadar IL-1, IL-6, dan TNF-α sekret hidung. Kata kunci: gangguan tidur, IL-1, IL-6, TNF-α, Pelargonium sidoides, rinosinusitis kronik alergi tanpa polip.  ABSTRACTBackground: Chronic rhinosinusitis without nasal polyps is inflammation of the nasal and paranasal sinus mucosa that lasts more than 12 weeks. It has multifactorial etiologies, and allergy is the most common. Its main symptoms are nasal congestion, runny nose, facial pain, smell disturbance, and can cause sleep disturbances. Sleep disturbances caused by nasal congestion and increased of inflammatory mediators IL-1, IL-6, and TNF-α. Purpose: To prove effectiveness of Pelargonium sidoides extract as adjuvant therapy in allergic chronic rhinosinusitis without nasal polyps accompanied by sleep disturbances. The indicators are improvement of clinical signs and symptom, and decreased level of IL-1, IL-6, and TNF-α nasal secretions. Methods: Quasi-experimental design with 20 samples, dividedinto two groups. First group treated with isotonic nasal saline solution, corticosteroid nasal spray, and extract of Pelargonium sidoides. Second group (control) were not given extract of Pelargonium sidoides. Clinical symptoms were measured with TNSS, VAS, and nasoendoscopy. Qualityof Life measured by RQLQ and SNOT-20. Results: TNSS (p= 0.001), nasoendoscopy score, VAS nasal congestion (p=0,018), rinorrhea (p=0,02) facial pain (0,008), and improving RQLQ activity (p= 0.003), sleep (p=0.001), non-nose/eye symptoms (p=0,005), and emotional (p=0,01) in the treated group significanly difference compare to the control group based on Mann-Whitney tes. No significant difference in SNOT-20 score , and decreased levels of IL-1, IL-6, and TNF-α. Conclusion: Pelargonium sidoides extract can be used as adjuvant therapy of chronic allergic rhinosinusitis without nasal polyps with sleep disturbance, but not supported by decrease of IL-1, IL-6, and TNF-α.nasal secretion.Keywords: IL-1, IL-6, TNF-α, Pelargonium sidoides, allergic chronic rhinosinusitis without nasal polyps, sleep disturbance.

scholarly journals Hypertrophy of adenoid vegetation: causes and methods of treatment

2019 ◽  
pp. 63-66
Author(s):  
Svetlana Yaremchuk
Keyword(s):  
Food Allergy ◽  
Nasal Congestion ◽  
Specific Ige ◽  
Nasal Discharge ◽  
Food Allergens ◽  
Nasal Breathing ◽  
Breathing Disorders ◽  
Screening Study ◽  
A Prospective Study ◽  
Methods Of Treatment

Topicality: Nasal congestion, nasal breathing disorders and nasal discharge are the most common complaints that parents of ill children refer to an otolaryngologist and pediatrician. The prevalence of allergic pathology in patients with adenoid vegetation hypertrophy (AН) varies from 22 to 73% according to various authors. Aim: To determine the prevalence of allergic rhinitis among patients with hypertrophy of adenoid vegetations, a prospective study was conducted. Materials and methods: 50 children with hypertrophy of adenoid vegetation aged 4 to 14 years were examined. A comprehensive screening study to detect specific IgE sensitization to the most common inhalation and food allergens. Results: Sensitization to inhaled allergens was detected in 48% of cases. In 8% of cases it coincided with food with food allergy. Only food allergy was detected in 1 child (2%). Timely etiopathogenetic therapy with topical nasal corticosteroids in patients with AN will avoid relapses after adenoidectomy and normalize nasal breathing, and in some cases, avoid surgery.

scholarly journals RHINITIS MEDICAMENTOSA: PRINCIPLES OF DIAGNOSIS AND TREATMENT

2021 ◽  
Vol 2021 (4) ◽  
pp. 50-54
Author(s):  
Ye. Bogomolov ◽  
S. V. Zaikov ◽  
S. O. Zubchenko
Keyword(s):  
Nasal Mucosa ◽  
Nasal Congestion ◽  
Diagnosis And Treatment ◽  
Common Symptom ◽  
Nasal Breathing ◽  
Drug Induced ◽  
National Medical ◽  
Nasal Decongestants ◽  
Medical University ◽  
Rhinitis Medicamentosa

RHINITIS MEDICAMENTOSA: PRINCIPLES OF DIAGNOSIS AND TREATMENT Ye. Bogomolov1, S. V. Zaikov2, S. O. Zubchenko3 1 National Pirogov memorial medical university, Vinnitsya, Ukraine 2 Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine 3 Danylo Halytsky Lviv National Medical University, Lviv, Ukraine Abstract. Nasal congestion is a common symptom that affects up to 30 % of the world’s population. Uncontrolled intake of nasal decongestants to relieve nasal congestion leads to rhinitis medicamentosa (RM), a subtype of drug-induced rhinitis, which is a chronic dysfunction of the nasal mucosa due to prolonged use of local vasoconstrictors. RM occurs with equal frequency in men and women, but is more common in young and middle-aged adults, and the described incidence into laryngological clinics ranges from 1 % to 7 %. In Ukraine, the problem is not statistically studied, but almost 2 billion hryvnias were spent by Ukrainians on the purchase of 40 million packages of decongestants per year (August 2019 — July 2020), which means that every Ukrainian, including newborns, used at least 1 package of this drug. The main diagnostic criteria for RM, in addition to detecting the presence of nasal obstruction (hyperemia, edema of the nasal mucosa with disorders of nasal breathing and nasal congestion) and reduction of edema of the nasal mucosa with the use of vasoconstrictors, are indications of a history of long-term nasal decontamination. The only drugs whose efficacy in RM has been proven not only in experimental but also in clinical randomized placebo-controlled studies are intranasal glucocorticoids (GCS). Currently, intranasal GCS are considered the most effective drugs available for the treatment of RM. Key words: rhinitis medicamentosa, nasal congestion, nasal decongestants.

Sign in / Sign up

Export Citation Format

Share Document